Skip to content Skip to footer
Subscribe Now
New Drug Designations - January 2025
INSIGHTS+

New Drug Designations – January 2025

Shots:    PharmaShots’ Designation Report provides a concise overview of the latest drug designations granted by major regulatory authorities, including the FDA, EMA, MHLW, and NMPA  The January 2025 report covers designations granted to 53 drugs and 9 medical devices, spanning 18 small molecules, 13 biologics, 13 cell and gene therapies & 9 medical devices among…
February 28, 2025

Read more

IPO Top 20 2024
TOP 20

Top 20 Healthcare IPOs of 2024

Shots: Initial Public Offerings (IPOs) serve as a strategic avenue for private healthcare companies to enhance liquidity, secure capital, and strengthen market presence. Beyond fundraising, going public often paves the way for strategic partnerships and expanded industry influence. Galderma led the IPO landscape in 2024, raising a staggering $2.54B, followed by BrightSpring Health Services and…
February 27, 2025

Read more

Viewpoints_Mina Makar
VIEWPOINTS

A Retrospective Analysis on Cardiac Amyloidosis: Mina Makar from AstraZeneca in an Illuminating Conversation with PharmaShots

Shots:  A UK observational study spanning 17 years shows a 2.9-fold increase in Cardiac Amyloidosis diagnoses, highlighting significant progress in awareness among healthcare professionals and advancements in diagnostic tools  The study underscores the importance of improving the identification and treatment of Cardiac Amyloidosis, particularly in cases with overlapping conditions such as heart failure  Mina Makar,…
February 24, 2025

Read more

WEEKLY SNAPSHOT

PharmaShots Weekly Snapshots (February 17th, 2025 – February 21th, 2025) 

This week PharmaShots’ news was all about the updates on Clinical Trials, Regulatory, Pharma, MedTech, M&A, Animal Health, COVID 19 & Biosimilars. Check out our full report below:      AstraZeneca Presents Post-Hoc Data from P-III (NIAGARA) Trial of Imfinzi in Muscle-Invasive Bladder Cancer Patients regardless of Complete Pathology Response at ASCO GU 2025  Read More: AstraZeneca  Exelixis Presents 5-year…
February 21, 2025

Read more

WEEKLY SNAPSHOT

PharmaShots Weekly Snapshots (February 10th, 2025 – February 14th, 2025)

This week PharmaShots’ news was all about the updates on Clinical Trials, Regulatory, Pharma, MedTech, M&A, Animal Health & Biosimilars. Check out our full report below:      Eli Lilly Reveals VIVID-2 Study Data of Omvoh to Treat Crohn's Disease  Read More: Eli Lilly  Regeneron Reveals Data from Extended P-III (PULSAR) Trial of Eylea HD for Wet Age-related Macular Degeneration  Read…
February 14, 2025

Read more

Reuters Events Digital Health 2025
EVENTS

Reuters Events: Digital Health 2025

Join us for Reuters Events Digital Health 2025 on 12-13 May in Nashville, where we tackle the critical issues plaguing the healthcare sector today. As organizations face a stretched workforce and an outdated digital infrastructure, the urgency for transformation has never been greater. Current models of care are unsustainable, especially when addressing the diverse needs of an…
February 14, 2025

Read more

PharmaShots Magazine-February 2025 Edition
MAGAZINE

PharmaShots Magazine-February 2025 Edition

After successfully navigating the healthcare landscapes of the US, EU, and China, PharmaShots Magazine brings a comprehensive take on the Japanese Healthcare System. Japan ranked second in healthcare innovation owing to diverse positive parameters like advanced medical infrastructure, learned professionals, and more. In 2023, Japan allocated 11.4 percent of its GDP to enhancing healthcare capabilities.  …
February 13, 2025

Read more

Load more